Figure 3. Effects of empagliflozin treatment on excess ¹³C enrichment in glucose.

Contribution of [U-¹³C₃] glycerol to glucose production via hepatic gluconeogenesis in participants treated with empagliflozin (top panel) and matching placebo (bottom panel). There was a statistically significant 6.5% increase in the area under the curve for ¹³C enrichment in glucose in the empagliflozin treated group and no treatment difference with placebo. Baseline to follow-up comparisons were made using mixed linear models to account for all time points at each visit.